skip to content

Trading statements

Dechra growth driven by core portfolio

06 July 2017 08:17

Dechra Pharmaceuticals said trading in the year ended 30 June was strong and in line with management expectations, with a good performance from the core business complemented by the successful integration and performance of acquisitions.

Reported group revenue for the period increased by c.28% at constant exchange rate (c.45% at actual exchange rate).

It said numerous product registrations had been achieved during the year, including approval by the FDA for the first major product from the Putney pipeline, a companion animal product (CAP) generic antibiotic, Amoxi-clav.

Chief executive Ian Page said: "As we complete our 20th year since the inception of Dechra, we are pleased to report that the group has delivered another strong financial performance.

"This has been driven by growth from our core portfolio, good market penetration from recent pipeline launches and the successful integration and performance of the acquisitions made in the preceding financial year.

"We start the new financial year in a good position."

At 8:17am: (LON:DPH) Dechra Pharmaceuticals PLC share price was -9p at 1699p

Story provided by

Related Company: DPH

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.